Document
Generically Dependent Continuant
RDF description of Recurrent diffuse alveolar haemorrhage in a patient with systemic lupus erythematosus: Long-term benefit of rituximab - http://orbis.uaslp.mx/vivo/individual/scopus3169
diffuse alveolar haemorrhage; rituximab; systemic lupus erythematosus amlodipine; azathioprine; beta adrenergic receptor blocking agent; cyclophosphamide; enalapril; hemoglobin; methotrexate; methylprednisolone; mycophenolic acid 2 morpholinoethyl ester; neutrophil cytoplasmic antibody; prednisone; rituximab; abdominal pain; adult; anamnesis; article; artificial ventilation; cachexia; case report; cell infiltration; computer assisted tomography; cryoglobulinemia; diffuse alveolar hemorrhage; disease activity; female; follow up; hemoptysis; human; hypertension; hypoxemia; immunosuppressive treatment; impedance; kidney biopsy; long term care; lung alveolus; lung hemorrhage; lung lavage; nuclear magnetic resonance imaging; posterior reversible encephalopathy syndrome; priority journal; recurrent disease; systemic lupus erythematosus; vasculitis; Antibodies, Monoclonal, Murine-Derived; Cachexia; Female; Hemorrhage; Humans; Immunosuppressive Agents; Lung Diseases; Lupus Erythematosus, Systemic; Posterior Leukoencephalopathy Syndrome; Pulmonary Alveoli; Recurrence; Young Adult
Diffuse alveolar haemorrhage (DAH) is an uncommon complication of systemic lupus erythematosus (SLE), and recurrences of DAH with remission periods are unusual. We describe a young woman with cachexia as the initial manifestation of SLE who presented posterior reversible encephalopathy syndrome (PRES), intestinal vasculitis and four episodes of DAH even though she was receiving combined immune suppressive therapy. After treatment with rituximab (RTX) the patient has not presented further episodes of DAH. © 2012 The Author(s).
Recurrent diffuse alveolar haemorrhage in a patient with systemic lupus erythematosus: Long-term benefit of rituximab
amlodipine, 103129-82-4, 736178-83-9, 88150-42-9; azathioprine, 446-86-6; cyclophosphamide, 50-18-0; enalapril, 75847-73-3; hemoglobin, 9008-02-0; methotrexate, 15475-56-6, 59-05-2, 7413-34-5; methylprednisolone, 6923-42-8, 83-43-2; mycophenolic acid 2 morpholinoethyl ester, 116680-01-4, 128794-94-5; prednisone, 53-03-2; rituximab, 174722-31-7; Antibodies, Monoclonal, Murine-Derived; Immunosuppressive Agents; rituximab
Article
Information Content Entity